The stock of Frontline Plc (NYSE: FRO) has decreased by -2.34 when compared to last closing price of 18.40. Despite this, the company has experienced a 0.73% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-20 that TUS+VEN+AZA triplet achieves complete remissions (CRs) and minimal residual disease (MRD)-negativity with favorable safety in newly diagnosed AML patients Completed 40 mg and 80 mg TUS dose cohorts; no prolonged myelosuppression or dose-limiting toxicities No dose reductions required to the standard-of-care therapy with 40 mg and 80 mg TUS dose cohorts CSRC endorsed escalation to 120 mg TUS dosing First patient dosed with 120 mg TUS triplet and enrollment continues SAN DIEGO and TORONTO, May 20, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today announced that the Cohort Safety Review Committee (CSRC) monitoring Aptose’s Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has approved escalating from 80 mg dose TUS to 120 mg dose TUS based on its favorable review of safety and efficacy data from patients in the first two cohorts of the trial. Dosing of the first subject at the 120 mg TUS dose level has commenced.
Is It Worth Investing in Frontline Plc (NYSE: FRO) Right Now?
Frontline Plc (NYSE: FRO) has a higher price-to-earnings ratio of 8.07x compared to its average ratio, The 36-month beta value for FRO is at 0.31. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for FRO is 143.15M, and currently, shorts hold a 5.28% of that float. The average trading volume for FRO on May 20, 2025 was 3.05M shares.
FRO’s Market Performance
FRO’s stock has seen a 0.73% increase for the week, with a 20.93% rise in the past month and a 3.10% gain in the past quarter. The volatility ratio for the week is 2.51%, and the volatility levels for the past 30 days are at 2.95% for Frontline Plc The simple moving average for the last 20 days is 4.01% for FRO stock, with a simple moving average of -3.01% for the last 200 days.
Analysts’ Opinion of FRO
Many brokerage firms have already submitted their reports for FRO stocks, with Kepler repeating the rating for FRO by listing it as a “Hold.” The predicted price for FRO in the upcoming period, according to Kepler is $15.83 based on the research report published on December 12, 2024 of the previous year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see FRO reach a price target of $30. The rating they have provided for FRO stocks is “Buy” according to the report published on October 07th, 2024.
Jefferies gave a rating of “Buy” to FRO, setting the target price at $30 in the report published on March 21st of the previous year.
FRO Trading at 12.31% from the 50-Day Moving Average
After a stumble in the market that brought FRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.86% of loss for the given period.
Volatility was left at 2.95%, however, over the last 30 days, the volatility rate increased by 2.51%, as shares surge +20.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.52% upper at present.
During the last 5 trading sessions, FRO rose by +1.43%, which changed the moving average for the period of 200-days by -25.20% in comparison to the 20-day moving average, which settled at $17.28. In addition, Frontline Plc saw 26.64% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for FRO
Current profitability levels for the company are sitting at:
- 0.36 for the present operating margin
- 0.38 for the gross margin
The net margin for Frontline Plc stands at 0.24. The total capital return value is set at 0.13. Equity return is now at value 21.46, with 8.19 for asset returns.
Based on Frontline Plc (FRO), the company’s capital structure generated 0.62 points at debt to capital in total, while cash flow to debt ratio is standing at 0.2. The debt to equity ratio resting at 1.6. The interest coverage ratio of the stock is 2.44.
Currently, EBITDA for the company is 1.15 billion with net debt to EBITDA at 3.05. When we switch over and look at the enterprise to sales, we see a ratio of 3.57. The receivables turnover for the company is 14.91for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.39.
Conclusion
In conclusion, Frontline Plc (FRO) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
